Chromos and Pain Therapeutics sign cell line engineering agreement
Chromos Molecular Systems Inc. announced that it has entered into an agreement with Pain Therapeutics, Inc. to develop a cell line using Chromos' ACE System. Under the agreement, Chromos will engineer cell lines specific for the Expression of a proprietary monoclonal antibody for Pain Therapeutics using the ACE System. Pain Therapeutics has the right to use the cell lines for scale up and manufacture of the proprietary monoclonal antibody, following the cell line engineering phase of the agreement. The financial details of the agreement were not disclosed.
Chromos' ACE System is a versatile and potent biological engineering system based on proprietary artificial chromosome technology that facilitates the rapid engineering of stable high expressing production cell lines for the clinical and commercial manufacture of biopharmaceuticals. Recent data generated by one of Chromos' partners has shown that cell lines engineered by Chromos using the ACE System are capable of achieving monoclonal antibody yields of greater than 4 g/L in a non-optimized bioreactor system, a four-fold improvement over the partner's original cell line. Chromos has also used an ACE System-derived cell line to manufacture its lead product, CHR-1103.
Other news from the department business & finance
